Autologous Whole Blood Management for Reduction of Blood Product Transfusion in Adult Cardiac Surgery Patients: a Local Feasibility/Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this pilot trial is to test a protocol for a planned Canada-wide clinical trial looking at whether or not the use of a patients own blood works as good as the current standard of care using donated blood products to reduce blood loss in adult patients having heart surgery. The main questions this study aims to answer are: * Is the protocol practical, effective, and efficient. * Does the use of a patients own blood lower the following: bleeding, the amount donated blood products given, and complications. Participants will be separated into two groups by a process that is like flipping a coin. One group will donate blood to themselves in the operating room and get their own blood back after surgery. The other group will be given blood products donated by other humans to treat the bleeding after heart surgery. Researchers will compare both groups to see if patients that get their own blood have fewer donated blood products given at time of heart surgery and have less complications after surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: t
View:

• Adult (≥18 yr)

• Surgical patients at the Mazankowski Alberta Heart Institute

• High risk for acquired coagulopathy

Locations
Other Locations
Canada
University of Alberta
RECRUITING
Edmonton
Contact Information
Primary
Angela R Neufeld, MD
angela.neufeld@ualberta.ca
(780) 407-8861
Time Frame
Start Date: 2024-06-05
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 64
Treatments
Experimental: Autologous Whole Blood Management
Intraoperative high volume autologous whole blood withdrawal prior to cardiopulmonary bypass (CPB) with re-transfusion following weaning from CPB.
Active_comparator: Allogenic and Derivative Transfusion
Control arm participants will receive standard care involving transfusion of plasma, platelets, cryoprecipitate, and/or lyophilized concentrates following weaning from CPB.
Related Therapeutic Areas
Sponsors
Collaborators: Alberta Innovates Health Solutions, University Hospital Foundation, EPICORE Centre
Leads: University of Alberta

This content was sourced from clinicaltrials.gov